New York's AngioDynamics lands FDA clearance for a new BioFlo product and takes charge of distribution partner Medcomp's Celerity tip locater after an FDA loss.
LeMaitre Vascular says it plans to lay off about 10% of its workforce, or roughly 30 workers, despite posting record sales during the 4th quarter.
LeMaitre Vascular (NSDQ:LMAT) said it plans to lay off about 10% of its workforce, or about 30 employees, even as it comes off of a record sales performance during the 4th quarter.
Evena Medical says it pulled in $5 million in a Series B it hopes will eventually reach $15 million and announced a distribution deal in the Middle East for its Eyes-On vascular imaging glasses.
Evena Medical said it landed $5 million in a Series B funding round and inked a distribution deal in the Middle East and North Africa.
Silicon Valley-based Evena said it hopes the financing round will eventually reach $15 million. This tranche of the round comes from its new, unnamed distribution partner in 15 Middle Eastern and North African countries.
Admedus lands FDA 510(k) clearance for its CardioCel, a tissue regeneration product designed to treat a range of cardiovascular and vascular defects.
Admedus won 510(k) clearance from the U.S. FDA for its CardioCel cardiovascular scaffold.
Perth, Australia and Minneapolis, Minn.-based Admedus is developing implantable regenerative technologies. CardioCel, the company's 1st product, is a pure collagen, bio-compatible regenerative tissue scaffold.
Sapheon lands approval from Health Canada for its VenaSeal Sapheon closure system, a medical adhesive used for treating venous reflux disease.
Sapheon secured approval from Health Canada for its VenaSeal Sapheon closure system, used in the treatment of varicose veins.
Morrisville, N.C.-based Sapheon develops treatments for vascular disease, its flagship product being the VenaSeal, a medical adhesive which seals blood vessels using a special glue. The company is currently working towards getting pre-market approval from the U.S. FDA.
W.L. Gore enrolls its 1st patient in the Gore TAG thoracic branch endoprosthesis LSA feasibility study in the U.S.
W.L. Gore & Associates enrolled the 1st patient in its U.S. Gore TAG thoracic branch endoprosthesis LSA feasibility study in hopes of landing FDA approval for treatment of thoracic aortic aneurysms in the left subclavian artery.
Covidien participates in the Series A round for Fire1, a stealthy Irish medical device startup that could be a player in the vascular space.
Covidien (NYSE:COV) said it participated in the Series A round for stealthy Irish medical device startup Fire1.